EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Novel PAX3::MAML3 Fusion Identified in Alveolar Rhabdomyosarcoma, Using DNA Methylation Profiling to Expand the Genetic Spectrum of “Fusion-Positive” Cases

Josephine K Dermawan, Faizan Malik, John M Gross, Ezra Baraban, Christine Pratilas, Wadad Mneimneh, Matteo Trucco, Wenyue Sun, Frederic G Barr, Felipe D'Almeida Costa, Karen J Fritchie

Modern Pathology · 2024

DOI: 10.1016/j.modpat.2024.100594 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Pathology, 2024. Verfasst von Josephine K Dermawan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Alveolar, DNA Methylation, PAX3 Transcription Factor, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alveolar rhabdomyosarcoma (ARMS) with FOXO1 gene rearrangements is an aggressive pediatric rhabdomyosarcoma subtype that is prognostically distinct from embryonal rhabdomyosarcoma and fusion-negative ARMS. Here, we report 2 cases of ARMS with PAX3::MAML3 fusions. The tumors arose in an infant and an adolescent as stage IV metastatic disease (by Children's Oncology Group staging system). Histologically, both cases were small round blue cell tumors arranged in vague nests and solid sheets that were diffusely positive for desmin and myogenin. By methylation profiling and unsupervised clustering analysis, the tumors clustered with ARMS with classic FOXO1 rearrangements and ARMS with variant PAX3::NCOA1/INO80D fusions, but not with biphenotypic sinonasal sarcoma (BSNS) with PAX3::MAML3/NCOA2/FOXO1/YAP1 fusions nor with other small round blue cell tumors, including embryonal rhabdomyosarcoma. The differentially methylated genes between ARMS and BSNS were highly enriched in genes involved in myogenesis, and 21% of these genes overlap with target genes of the PAX3::FOXO1 fusion transcription factor. On follow-up after initiation of vincristine/actinomycin/cyclophosphamide chemotherapy, the tumors showed partial and complete clinical responses, consistent with typical upfront chemotherapy responsiveness of ARMS with the classic FOXO1 rearrangement. We conclude that PAX3::MAML3 is a novel variant fusion of ARMS, which displays a methylation signature distinct from BSNS despite sharing similar PAX3 fusions. These findings highlight the utility of methylation profiling in classifying ARMS with noncanonical fusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhabdomyosarcoma, AlveolarDNA MethylationPAX3 Transcription FactorOncogene Proteins, FusionTrans-ActivatorsDNA-Binding ProteinsHumansAdolescentMaleInfantFemaleTranscription FactorsPaired Box Transcription FactorsBiomarkers, Tumor

Stichwörter der Autor:innen

PAX3::MAML3alveolar rhabdomyosarcomamethylationsarcomas

Substanzen

PAX3 Transcription FactorPAX3 protein, humanOncogene Proteins, FusionMAML3 protein, humanTrans-ActivatorsDNA-Binding ProteinsTranscription FactorsPaired Box Transcription FactorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
  • Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee.
  • Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland.
  • Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland.
  • Department of Pediatric Hematology, Oncology & Bone Marrow Transplant, Cleveland Clinic, Cleveland, Ohio.
  • Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Förderung

  • National Cancer Institute

Zitieren

APA

Dermawan, J. K., Malik, F., Gross, J. M., Baraban, E., Pratilas, C., Mneimneh, W., Trucco, M., Sun, W., Barr, F. G., D'Almeida Costa, F., & Fritchie, K. J. (2024). Novel PAX3::MAML3 Fusion Identified in Alveolar Rhabdomyosarcoma, Using DNA Methylation Profiling to Expand the Genetic Spectrum of “Fusion-Positive” Cases. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100594

Vancouver

Dermawan JK, Malik F, Gross JM, Baraban E, Pratilas C, Mneimneh W, et al. Novel PAX3::MAML3 Fusion Identified in Alveolar Rhabdomyosarcoma, Using DNA Methylation Profiling to Expand the Genetic Spectrum of “Fusion-Positive” Cases. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100594

BibTeX
@article{Dermawan2024,
  author = {Dermawan, Josephine K and Malik, Faizan and Gross, John M and Baraban, Ezra and Pratilas, Christine and Mneimneh, Wadad and Trucco, Matteo and Sun, Wenyue and Barr, Frederic G and D'Almeida Costa, Felipe and Fritchie, Karen J},
  title = {Novel PAX3::MAML3 Fusion Identified in Alveolar Rhabdomyosarcoma, Using DNA Methylation Profiling to Expand the Genetic Spectrum of “Fusion-Positive” Cases},
  journal = {Modern Pathology},
  year = {2024},
  doi = {10.1016/j.modpat.2024.100594}
}
Kostenlos starten →